Skip to content

Clinical Study of Bone Wax.

Post Market Clinical Follow Up Study of Bone Wax.

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/12/038668
Enrollment
31
Registered
2021-12-15
Start date
Unknown
Completion date
Unknown
Last updated
2022-02-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: O- Medical and Surgical

Interventions

Intervention1: Surgical Bone Wax: Bone wax stick with a weight of 2.5 gms . Frequency of usage is once. Duration is 2to3 hours. Control Intervention1: Not Applicable: Not Applicable

Sponsors

Mr Ashish Baran Dhara
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Subject with Informed consent. Adult patients who are >= 18 years old, have undergone neurosurgery. Subject using Bone Wax to control bleeding from bone surfaces. Subject with known sensitivities or allergies to bees wax, pollen grains, paraffin wax and iso propyl palmitate.

Exclusion criteria

Exclusion criteria: Subjects without informed consent. Subject requiring rapid osseous regeneration and fusion.

Design outcomes

Primary

MeasureTime frame
The primary objective of this post market clinical study is to assess the clinical performance, safety and acceptability of the Bone Wax. End points 1) Qualitative determination of bleeding and hemostatic action during application graded by the surgeon using the mild, moderate, and severe for bleeding and complete, moderate, minimal, and failure for hemostatic action 2) Occurrence of re-bleeding during the operation will be noted. 3) Wound infection or other complications within 15 days post procedure 4) Ease of use using Likertâ??s scale (1-5) Timepoint: 3 to 4 months

Secondary

MeasureTime frame
The Secondary Objective is to determine any undesirable events under normal condition of use and identify the presence of any new emergent risks, known and unknown residual risk. The study will focus on identifying possible systematic misuse or off-label use of the device.Timepoint: 3 to 4 months

Countries

India

Contacts

Public ContactDr Murali Mohan S

Sagar Hospitals

drmurali78@gmail.com9483861505

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026